• In May 2026, PROCEPT BioRobotics reported two milestones in its WATER IV prostate cancer program: full enrollment of the 280‑patient randomized trial comparing Aquablation therapy with radical prostatectomy, and FDA IDE approval for a second global randomized study comparing Aquablation with active surveillance.
• By positioning Aquablation against both the surgical standard of care and active surveillance, PROCEPT is testing whether its robotic waterjet approach can expand treatment options while tracking long‑term disease control and quality‑of‑life outcomes over ten years.
• We’ll now examine how these WATER IV milestones, especially the new FDA‑approved trial versus active surveillance, affect PROCEPT BioRobotics’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can become a foundational urology platform across BPH and prostate cancer while the company works through ongoing losses and a relatively high valuation. The WATER IV milestones strengthen the long term clinical story, but the key near term catalyst still centers on accelerating Aquablation adoption in hospitals, while the biggest risk remains heavy dependence on a single platform in a competitive, cost conscious market.

Among recent announcements, the European Association of Urology’s upgrade of Aquablation to a strong recommendation for BPH management is especially relevant. Together with the new prostate cancer trials, it highlights how growing guideline support and expanding indications could reinforce utilization of the HYDROS/Aquablation ecosystem, which is central to PROCEPT’s installed base growth and recurring consumables revenue, even as reimbursement and competitive pressures remain important watchpoints.

Yet against this opportunity, investors should also weigh how rising competition and reimbursement pressure could still limit adoption and compress margins over time...

PROCEPT BioRobotics’ narrative projects $608.2 million revenue and $77.8 million earnings by 2029. This requires 23.6% yearly revenue growth and a $180.3 million earnings increase from -$102.5 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming around US$607,000,000 of revenue by 2029 but still see reimbursement and competition as limiting factors, so you may want to compare that more cautious view with your own expectations in light of the new WATER IV data path.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth 27% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.